Novel Brachytherapy Plaque for Dural Irradiation

描述(申请人提供)：脊柱脊索瘤和软骨肉瘤 通常伸入椎管并撞击硬脑膜和脊髓。在.期间 切除时，病变从硬脑膜剥离，形成阳性边缘。 在目前的外照射治疗下，肿瘤床可以有效地 治疗过了。然而，因为硬脑膜和脐带表面之间的距离是 只有2到2.5 mm，硬脑膜的剂量必须被限制在次优水平。至 在不过度照射脊髓的情况下，增加硬脑膜的剂量，建议 术中使用放射性药物补充剂量 释放贝塔的斑块。有了这个斑块，脐带表面的剂量将仅为 硬脑膜剂量的10%和脐带中部的剂量 会少得多。所提供的额外剂量将显著 增加肿瘤控制的概率。 这个项目的具体目标是开发一种新型的贝塔发射 术中硬脑膜照射的近距离放射治疗斑块。两种不同的 将对发射贝塔的放射性核素进行测试，它们的剂量测定将 对临床应用进行评估。这项评估的结果将导致 该斑块的优化设计，将进行台架测试，以准备 临床试验。 建议的商业应用：不可用

DESCRIPTION (provided by applicant): Chordomas and chondrosarcomas of the spine commonly extend into the spinal canal and impinge on the dura and cord. During resection, the lesion is peeled from the dura, resulting in positive margins. With current external beam radiation therapy, the tumor bed can be effectively treated. However, because the distance between the dura and cord surface is only 2 to 2.5 mm, dose to the dura must be limited to a suboptimal level. To increase the dose to the dura without over-irradiating the cord, it is proposed to intraoperatively deliver a supplemental dose using a radioactive beta-emitting plaque. With this plaque, dose to the cord surface would be only 10 percent of the dose to the dura and the dose to the mid portion of the cord would be substantially less. The additional dose delivered will markedly increase the probability of tumor control. The specific aim of this program is to develop a novel beta-emitting brachytherapy plaque for intraoperative irradiation of the dura. Two different beta-emitting radionuclides will be tested and their dosimetry will be evaluated for clinical utility. The results of this evaluation will lead to an optimum design of this plaque, which will be bench-tested in preparation for clinical trial. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE